Antisense oligonucleotide treatments for psoriasis

Bibliography

• ZAMECNIK PC, STEPHENSON ML:Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA (1978) 75:280–284.
   PubMed Web of Science ®Google Scholar
• •Seminar paper on antisense mechanism of action.
   Google Scholar
• AGRAWAL S, IYER RP: Perspectives in antisense therapeutics. Pharmacol. The]: (1997) 76:151–160.
   PubMed Web of Science ®Google Scholar
• CROOKE ST: An overview of progress in antisense therapeutics. Antisense Nucleic Add Drug Dev. (1998) 8:115–122.
   PubMedGoogle Scholar
• •Key review of the developments in antisense therapy.
   Google Scholar
• JABS DA, GRIFFITHS PD: Fomivirsen for the treatment of cytomegalovirus retinitis. Am. J. Ophthalmol. (2002) 133:552–556.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M: Psoriasis. Lancet (2003) 361:1197–1204.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB AB: Immunologic mechanisms in psoriasis. Am. Acad. Dermatol. (1988) 18:1376–1380.
   PubMed Web of Science ®Google Scholar
• NICKOLOFF BJ, MITRA RS, GREEN J, SHIMIZU Y, THOMPSON C, TURKA LA: Activated keratinocytes present bacterial-derived superantigens to T lymphocytes: relevance to psoriasis.Dermatol. Sci. (1993) 6:127–133.
   PubMedGoogle Scholar
• SZABO SK, HAMMERBERG C, YOSHIDA Y, BATA-CSORGO Z, COOPER KD: Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. Invest. Dermatol. (1998) 111:1072–1078.
   PubMed Web of Science ®Google Scholar
• CHIN YH, FALANGA V, CAI JP: Lymphocyte adhesion to psoriatic dermal endothelium: mechanism and modulation. J. Invest. Dermatol. (1990) 95:29S–31S.
   Google Scholar
• PRINZ JC, GROSS B, VOLLMER S et al: T cell clones from psoriasis skin lesions can promote keratinocyte proliferation M vitro via secreted products. Ear: Immunol. (1994) 24:593–598.
   PubMed Web of Science ®Google Scholar
• STRANGE P, COOPER KD,HANSEN ER et al.: T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation. Invest. Dermatol. (1993) 101:695–700.
   Google Scholar
• KRUEGER JG, KRANE JF,CARTER DM, GOTTLIEB AB: Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. Invest. Dermatol. (1990) 94:135S–140S.
   Google Scholar
• NICKOLOFF BJ, BONISH B,HUANG BB, PORCELLI SA: Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. Dermatol. Sci. (2000) 24:212–225.
   PubMed Web of Science ®Google Scholar
• NICKOLOFF BJ, WRONE-SMITH T: Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am. Pathol. (1999) 155:145–158.
   PubMed Web of Science ®Google Scholar
• ••Demonstrated the immunologicalinitiation of psoriasis.
   Google Scholar
• BATA-CSORGO Z, HAMMERBERG C, VOORHEES JJ, COOPER KD: Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia.Invest. Dermatol. (1995) 105:89S–94S.
   Google Scholar
• CATHER JC, MENTER A: Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin. Biol. Ther. (2003) 3:361–370.
   PubMed Web of Science ®Google Scholar
• FOGARTY RD, MCKEAN SC,WHITE PJ, ATLEY LM, WERTHER GA, WRAIGHT CJ: Sequence dependence of C5-propynyl-dU,dC-phosphorothioate oligonucleotide inhibition of the human IGF-I receptor: mRNA, protein, and cell growth. Antisense Nucleic Add Drug Dev. (2002) 12:369–377.
   PubMedGoogle Scholar
• KING LE JR, GATES RE,STOSCHECK CM, NANNEY LB:Epidermal growth factor/transforming growth factor alpha receptors and psoriasis.Invest. Dermatol. (1990) 95:10S–12S.
   Google Scholar
• MIURA H, SANO S, HIGASHIYAMA M, YOSHIKAWA K, ITAMI S: Involvement of insulin-like growth factor-I in psoriasis as a paracrine growth factor: dermal fibroblasts play a regulatory role in developing psoriatic lesions. Arch. Dermatol. Res. (2000) 292:590–597.
   PubMed Web of Science ®Google Scholar
• RISTOW HI: Increased synergistic effect ofEGF and IGF-I on DNA synthesis of cultured psoriatic keratinocytes. Dermatology (1997) 195:213–219.
   PubMed Web of Science ®Google Scholar
• WRAIGHT CJ, EDMONDSON SR, FORTUNE DW, VARIGOS G, WERTHER GA: Expression of insulin-like growth factor binding protein-3 (IGFBP-3) in the psoriatic lesion. Invest. Dermatol. (1997) 108:452–456.
   PubMed Web of Science ®Google Scholar
• WRAIGHT CJ, MURASHITA MM, RUSSO VC, WERTHER GA:A keratinocyte cell line synthesizes a predominant insulin-like growth factor-binding protein (IGFBP-3) that modulates insulin-like growth factor-I action. Invest. Dermatol. (1994) 103:627–631.
   PubMed Web of Science ®Google Scholar
• WRAIGHT CJ, WHITE PJ,MCKEAN SC et al.: Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth Factor I receptor antisense oligonucleotides. Nat. Biotechnol. (2000) 18:521–526.
   Google Scholar
• ••First demonstration of resolution ofpsoriasis by antisense oligonucleotide.
   Google Scholar
• FINLAY AY: Coping with psoriasis. Br. Med. J. (1995) 310:1673.
   PubMed Web of Science ®Google Scholar
• RAPP SR, FELDMAN SR, EXUM ML, FLEISCHER AB JR, REBOUSSIN DM: Psoriasis causes as much disability as other major medical diseases.' Am. Acad. Dermatol. (1999) 41:401–407.
   PubMed Web of Science ®Google Scholar
• LEIGH IM, PULFORD KA,RAMAEKERS FC, LANE EB: Psoriasis: maintenance of an intact monolayer basal cell differentiation compartment in spite of hyperproliferation. Br. Dermatol. (1985) 113:53–64.
   PubMed Web of Science ®Google Scholar
• WEINSTEIN GD, MCCULLOUGH JL, ROSS P: Cell proliferation in normal epidermis. Invest. Dermatol. (1984) 82:623–628.
   PubMed Web of Science ®Google Scholar
• GUVAKOVA MA, YAKUBOV LA, VLODAVSKY I, TONKINSON JL, STEIN CA: Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol Chem. (1995) 270:2620–2627.
   PubMed Web of Science ®Google Scholar
• SMYTH AP, ROOK SL, DETMAR M, ROBINSON GS: Antisense oligonucleotides inhibit vascular endothelial growth factor/vascular permeability factor expression in normal human epidermal keratinocytes. Invest. Dermatol. (1997) 108:523–526.
   PubMed Web of Science ®Google Scholar
• AKHTAR S, KOLE R, JULIANO RL: Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci. (1991) 49:1793–1801.
   PubMed Web of Science ®Google Scholar
• HOKE GD, DRAPER K, FREIER SM et al.: Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Adds Res. (1991) 19:5743–5748.
   PubMed Web of Science ®Google Scholar
• GLOVER JM, LEEDS JM, MANT TG et al.: Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). 1 Pharinacol Exp. The]: (1997) 282:1173–1180.
   Google Scholar
• YACYSHYN BR, BARISH C, GOFF J et al.: Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment. Phannacol Ther. (2002) 16:1761–1770.
   PubMed Web of Science ®Google Scholar
• YACYSHYN BR, CHEY WY, GOFF J et al.: Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut (2002) 51:30–36.
   PubMed Web of Science ®Google Scholar
• WAGNER RW, MATTEUCCI MD, LEWIS JG, GUTIERREZ AJ, MOULDS C, FROEHLER BC: Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science (1993) 260:1510–1513.
   PubMed Web of Science ®Google Scholar
• MONIA BP, LESNIK EA, GONZALEZ C et al.: Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression.Biol. Chem. (1993) 268:14514–14522.
   Google Scholar
• ARORA V, HANNAH TL, IVERSEN PL, BRAND RM: Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharm. Res. (2002) 19:1465–1470.
   PubMed Web of Science ®Google Scholar
• GRAY GD, BASU S, WICKSTROM E: Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3'-alkylamino oligodeoxynucleotides, 2'-0-methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids. Biochem. Pharmacol (1997) 53:1465–1476.
   PubMed Web of Science ®Google Scholar
• TS'0 PO, AURELIAN L, CHANG E, MILLER PS: Nonionic oligonucleotide analogs (Matagen) as anticodic agents in duplex and triplex formation. Ann. NY Acad. Sci. (1992) 660:159–177.
   PubMed Web of Science ®Google Scholar
• WHITE PJ, FOGARTY RD, LIEPE IJ, DELANEY PM, WERTHER GA, WRAIGHT CJ: Live confocal microscopy of oligonucleotide uptake by keratinocytesin human skin grafts on nude mice.J. Invest. Dermatol (1999) 112:887–892.
   PubMed Web of Science ®Google Scholar
• ALESSANDRINI F, STACHOWITZ S, RING J, BEHRENDT H: The level of prosaposin is decreased in the skin of patients with psoriasis vulgaris. J. Invest. Dermatol (2001) 116:394–400.
   PubMed Web of Science ®Google Scholar
• FARTASCH M: Epidermal barrier in disorders of the skin. Microsc. Res. Tech. (1997) 38:361–372.
   PubMed Web of Science ®Google Scholar
• HWANG SM, AHN SK, MENON GK, CHOI EH, LEE SH: Basis of occlusive therapy in psoriasis: correcting defects in permeability barrier and calcium gradient. Int. J. Dermatol (2001) 40:223–231.
   PubMed Web of Science ®Google Scholar
• KIM SD, HUH CH, SEO KI, SUH DH, YOUN JI: Evaluation of skin surface hydration in Korean psoriasis patients: a possible factor influencing psoriasis. Clin. Exp. Dermatol (2002) 27:147–152.
   PubMed Web of Science ®Google Scholar
• ROBERTS MS: Targeted drug delivery to the skin and deeper tissues: role of physiology, solute structure and disease. Clin. Exp. Pharmacol Physic] (1997) 24:874–879.
   PubMed Web of Science ®Google Scholar
• TAGAMI H: Racial differences on skin barrier function. Cutts (2002) 70:6–7.
   PubMed Web of Science ®Google Scholar
• WHITE PJ, GRAY AC, FOGARTY RD et al.: C-5 propyne-modified oligonucleotides penetrate the epidermis in psoriatic and not normal human skin after topical application. Invest. Dermatol (2002) 118:1003–1007.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of impaired barrierfunction in psoriasis.
   Google Scholar
• VLASSOV VV, BALAKIREVA LA, YAKUBOV LA: Transport of oligonucleotides across natural and model membranes. Biochim. Biophys. Acta (1994) 1197:95–108.
   PubMed Web of Science ®Google Scholar
• OLDENBURG KR, VO KT, SMITH GA, SELICK HE: Iontophoretic delivery of oligonucleotides across full thickness hairless mouse skin. I Pharm. Sci. (1995) 84:915–921.
   PubMed Web of Science ®Google Scholar
• REGNIER V, PREAT V: Localization of aFITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation. Pharm. Res. (1998) 15:1596–1602.
   PubMed Web of Science ®Google Scholar
• BERGAN R, CONNELL Y, FAHMY B, NECKERS L: Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res. (1993) 21:3567–3573.
   PubMed Web of Science ®Google Scholar
• MEHTA RC, STECKER KK,COOPER SR et al.: Intercellular adhesion molecule-1 suppression in skin by topicaldelivery of anti-sense oligonucleotides.J. Invest. Dermatol (2000) 115:805–812.
   Google Scholar
• ••First demonstration of topical efficacy ofantisense oligonucleotide in vivo.
   Google Scholar
• NOONBERG SB, GAROVOY MR, HUNT CA: Characteristics of oligonucleotide uptake in human keratinocyte cultures. J. Invest. Dermatol (1993) 101:727–731.
   PubMed Web of Science ®Google Scholar
• WINGENS M, VAN HOOIJDONK CA, DE JONGH GJ, SCHALKWIJK J, VAN ERP PE: Flow cytometric and microscopic characterization of the uptake and distribution of phosphorothioate oligonucleotides in human keratinocytes. Arch. Dermatol Res. (1998) 290:119–125.
   PubMed Web of Science ®Google Scholar
• HERTL M, NECKERS LM, KATZ SI: Inhibition of interferon-gamma-induced intercellular adhesion molecule-1 expression on human keratinocytes by phosphorothioate antisense oligodeoxynucleotides is the consequence of antisense-specific and antisense-non-specific effects. J. Invest. Dermatol (1995) 104:813–818.
   PubMed Web of Science ®Google Scholar
• NESTLE FO, MITRA RS, BENNETT CECHAN H, NICKOLOFF BJ: Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. Invest. Dermatol (1994) 103:569–575.
   PubMed Web of Science ®Google Scholar
• LEVIN AA: A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta (1999) 1489:69–84.
   PubMed Web of Science ®Google Scholar
• SRINIVASAN SK, IVERSEN P: Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. Clin. Lab. Anal. (1995) 9:129–137.
   PubMed Web of Science ®Google Scholar
• VITRAVENE STUDY GROUP: Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am. I Ophthalmol (2002) 133:484–498.
   PubMed Web of Science ®Google Scholar